antibioticsАнтибиотики и ХимиотерапияAntibiot Khimioter = Antibiotics and Chemotherapy0235-2990ООО «Издательство ОКИ»10.37489/0235-2990-2022-67-11-12-56-63antibiotics-985Research ArticleОБЗОРЫREVIEWSПерспективы фаготерапии бактериальных инфекций, связанных с оказанием медицинской помощиProspects for Phagоtherapy of Bacterial Infections Associated with the Provision of Medical Carehttps://orcid.org/0000-0001-8607-2395ДаудоваА. Д.DaudovaA. D.

Даудова Адиля Джигангировна — кандидат медицинских наук, доцент кафедры микробиологии и вирусологии.

Астрахань

Adilya D. Daudova — Candidate of Medical Sciences, Associate Professor of the Department of Microbiology and Virology, Astrakhan State Medical University  of the Ministry  of Health of Russia.

Astrakhan

https://orcid.org/0000-0003-0536-8149АбдрахмановаР. О.AbdrakhmanovaR. O.

Абдрахманова Радмила Охасовна — ассистент кафедры микробиологии и вирусологии.

Астрахань

Radmila O. Abdrakhmanova — Assistant of the Department of Microbiology and Virology, Astrakhan  State Medical University of the Ministry of Health  of Russia.

Astrakhan

https://orcid.org/0000-0003-2998-2864ЯсенявскаяА. Л.YasenyavskayaA. L.

Ясенявская Анна Леонидовна — кандидат медицинских наук,  доцент, руководитель Научно-исследовательского центра, доцент кафедры фармакогнозии, фармацевтической технологии и биотехнологии.

Бакинская ул., 121, Астрахань

Anna L. Yasenyavskaya — Candidate of Medical Sciences, Associate Professor, Head of the Research Center, Associate Professor of the Department of Pharmacognosy, Pharmaceutical Technology and Biotechnology, Astrakhan State Medical University of the Ministry of Health  of Russia.

121 Bakinskaya st., Astrakhan

yasen_9@mail.ruhttps://orcid.org/0000-0003-0428-2570ДеминаЮ. З.DeminaJu. Z.

Демина Юлия Заурбековна — ассистент кафедры микробиологии и  вирусологии.

Астрахань

Yuliya Z. Demina — Assistant  of the Department of Microbiology  and  Virology, Astrakhan  State Medical University  of the Ministry  of Health  of Russia.

Astrakhan

https://orcid.org/0000-0002-8918-8921РубальскийМ. О.RubalskyM. O.

Рубальский Максим Олегович — врач клинической лабораторной диагностики.

Астрахань

Maksim O. Rubalsky — Doctor  of Clinical Laboratory  Diagnostics, City Diagnostic Laboratory.

Astrakhan

https://orcid.org/0000-0002-2904-9276РубальскийО. В.RubalskyO. V.

Рубальский Олег Васильевич — доктор медицинских наук, профессор, заведующий кафедрой микробиологии и вирусологии.

Астрахань

Oleg  V. Rubalsky — Doctor  of Medical Sciences, Professor, Head  of the Department of Microbiology and  Virology, Astrakhan State Medical University  of the Ministry of Health  of Russia.

Astrakhan

https://orcid.org/0000-0001-5336-4455СамотруеваМ. А.SamotruevaM. A.

Самотруева Марина Александровна — доктор медицинских наук, профессор, заведующая кафедрой фармакогнозии, фармацевтической  технологии и биотехнологии.

Астрахань

Marina A. Samotrueva — MD, Professor, Head of the Department  of Pharmacognosy, Pharmaceutical Technology and Biotechnology of the Astrakhan  State  Medical University  of the Ministry  of Health  of Russia.

Astrakhan

https://orcid.org/0000-0003-4168-4851БашкинаО. А.BashkinaO. A.

Башкина Ольга Александровна — доктор медицинских наук, профессор, заведующая кафедрой факультетской педиатрии.

Астрахань

Olga  A. Bashkina — Doctor  of Medical Sciences, Professor, Head of the Department of Faculty Pediatrics, Astrakhan State Medical University  of the  Ministry  of Health  of Russia.

Astrakhan

Астраханский государственный медицинский университетРоссияAstrakhan State Medical UniversityRussian FederationГородская диагностическая лабораторияРоссияCity Diagnostic LaboratoryRussian Federation2022110220236711-125663Copyright © Даудова А.Д., Абдрахманова Р.О., Ясенявская А.Л., Демина Ю.З., Рубальский М.О., Рубальский О.В., Самотруева М.А., Башкина О.А., 20232023Даудова А.Д., Абдрахманова Р.О., Ясенявская А.Л., Демина Ю.З., Рубальский М.О., Рубальский О.В., Самотруева М.А., Башкина О.А.Daudova A.D., Abdrakhmanova R.O., Yasenyavskaya A.L., Demina J.Z., Rubalsky M.O., Rubalsky O.V., Samotrueva M.A., Bashkina O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.antibiotics-chemotherapy.ru/jour/article/view/985

Инфекции, связанные с оказанием медицинской помощи (ИСМП), являются медицинской и социально-экономической проблемой глобального масштаба. Внутрибольничные инфекции (ВБИ) занимают одно из ведущих мест в ряду причин смертности населения Российской Федерации. Порядка 60–70% всех ВБИ связаны с использованием медицинских имплантатов различного профиля. В биоплёнках предметов медицинского назначения с высокой вероятностью обнаруживаются Pseudomonas aeruginosa, различные виды  стрептококков, стафилококков, Escherichia coli, энтерококки (Enterococcus faecalis), Klebsiella pneumoniae, Proteus mirabilis, представители рода Acinetobacter. Отличительной особенностью микробов, вызывающих ИСМП, является поли- или даже панрезистентность микробов к рекомендуемым антимикробным препаратам. Поиск  методов и средств по её преодолению является приоритетной задачей современной медицины. Фаготерапия представляется одним из логичных и перспективных путей борьбы с бактериями, устойчивыми к общепринятой терапии. В статье изложены преимущества и негативные аспекты фаготерапии, представлен обзор успешного применения моно- и комбинированных препаратов бактериофагов в эксперименте и клинике, а также современные направления использования бактериофагов не только с лечебной, но и с профилактической целью, основанные на последних достижениях генной инженерии и биотехнологии.

Healthcare-associated infections (HAIs) are a global medical and socioeconomic problem. Nosocomial infections occupy one of the leading places among the causes of death in the Russian Federation. About 60–70% of all nosocomial infections are associated with the use of medical implants of various profiles. Pseudomonas aeruginosa, various types of streptococci, staphylococci, Escherichia coli, enterococci (Enterococcus faecalis), Klebsiella pneumoniae, Proteus mirabilis, and representatives of the genus Acinetobacter are highly  likely to be found  in biofilms of medical supplies. A distinctive feature of microbes that cause  HAIs is poly- or even  pan-resistance of microbes to recommended antimicrobials. The search  for methods and means to overcome is a priority task of modern medicine. Phage therapy seems to be one of the logical and promising ways to combat bacteria that are resistant to conventional therapy. The article outlines the advantages and disadvantages of phage therapy, provides an overview of the successful use of mono- and combined preparations of bacteriophages in the experiment and clinic, as well as modern directions for the use of bacteriophages not only for therapeutic, but also for prophylactic purposes, based on the latest achievements of genetic engineering and biotechnology.

бактериофагинфекциисвязанные с медицинской помощьюбиоплёнкифаготерапияbacteriophagehealthcare-associated infectionsbiofilmsphagotherapyРабота выполнена в рамках государственного задания Министерства здравоохранения Российской Федерации в части проведения НИР по теме «Разработка композиций для персонализированной антибактериальной терапии на основе вирулентных стафилококковых бактериофагов с контролируемой литической активностью».ReferencesКосова А.А., Чалапа В.И. Инфекции, связанные с оказанием медицинской помощи, в стационарах России: опыт мета-анализа заболеваемости. Здоровье населения и среда обитания — ЗНиСО. 2018; 12: 57–64.Kosova A.A., Chalapa V.I. Infections associated with giving medical care in hospitals of Russia: experience of meta analysis of morbidity. Public Health and Life Environment — PH&LE. 2018; 12: 57–64. (in Russian)Haque M., Sartelli M.О., McKimm J., Bakar M.A. Health care-associated infections — an overview. Infect Drug Resist. 2018; 11: 2321–2333. doi: 10.2147/idr.s177247.Haque M., Sartelli M.О., McKimm J., Bakar M.A. Health care-associated infections — an overview. Infect Drug Resist. 2018; 11: 2321–2333. doi: 10.2147/idr.s177247.Брусина Е.Б., Зуева Л.П., Ковалишена О.В., Стасенко В.Л., Фельдблюм И.В., Брико Н.И., Акимкин В.Г. Инфекции, связанные с оказанием медицинской помощи: современная доктрина профилактики. Часть 2. Основные положения. Эпидемиология и Вакцинопрофилактика. 2018;17 (6): 4–10. doi: 10.31631/2073-3046-2018-17-4-10.Brusina E.B., Zuyeva L.P., Kovalishena O.V., Stasenko V.L., Feldblium I.V., Briko N.I., Akimkin V.G. Healthcare-Associated Infections: Modern Doctrine of Prophylaxis. Part II. Basic Concept. Epidemiology and Vaccinal Prevention. 2018; 17(6): 4–10. doi: 10.31631/2073-3046-2018-17-4-10 (in Russian)Покровский В.И., Акимкин В.Г.,Брико Н.И.,Брусина Е.Б., Зуева Л.П., Ковалишена О.В., Стасенко В.Л., Тутельян А.В., Фельдблюм И.В., Шкарин В.В. Национальная концепция профилактики инфекций, связанных с оказанием медицинской помощи, и информационный материал по её положениям. Нижний Новгород, «Ремедиум-Поволжье», 2012; 84.Pokrovsky V.I., Akimkin V.G., Briko N.I., Brusina E.B., Zueva L.P., Kovalishena O.V., Stasenko V.L., Tutelyan A.V., Feldblum I. .V., Shkarin V.V. Nacional'naya koncepciya profilaktiki infekcij, svyazannyh s okazaniem medicinskoj pomoshchi, i informacionnyj material po ee polozheniyam. Nizhnij Novgorod, «Remedium-Povolzh'e», 2012; 84 (in Russian)Найговзина Н.Б., Попова А.Ю.,Бирюкова Е.Е.,Ежлова Е.Б.,Игонина Е.П., Покровский В.И., Акимкин В.Г., Тутельян А.В., Краевой С.А., Костенко Н.А., Брико Н.И., Брусина Е.Б., Зуева Л.П., Фельдблюм И.В., Шкарин В.В., Козлов Р.С., Стасенко В.Л., Голубкова А.А., Сухих Г.Т., Припутневич Т.В., Шмаков Р.Г.,Зубков В.В., Шкода А.С., Шумилов В.И., Митрохин С.Д., Ершова О.Н., Селькова Е.П., Гренкова Т.А., Иванов И.В., Швабский О.Р.,Шестопалов Н.В. Оптимизация системы мер борьбы и профилактики инфекций, связанных с оказанием медицинской помощи в Российской Федерации. Медицинский алфавит. 2017; 4 (38): 5–9.Naigovzina N.B., Popova A.Yu., Biryukova E.E., Ezhlova E.B., Igonina E.P., Pokrovsky V.I., Akimkin V.G., Tutelyan A.V., Kraevoy S. A., Kostenko N.A., Briko N.I., Brusina E.B., Zueva L.P., Feldblyum I.V., Shkarin V.V., Kozlov R.S., Stasenko V.L. ., Golubkova A.A., Sukhikh G.T., Priputnevich T.V., Shmakov R.G., Zubkov V.V., Skoda A.S., Shumilov V.I., Mitrokhin S.D., Ershova O.N., Selkova E.P., Grenkova T.A., Ivanov I.V., Shvabsky O.R., Shestopalov N.V. Optimizaciya sistemy mer bor'by i profilaktiki infekcij, svyazannyh s okazaniem medicinskoj pomoshchi v Rossijskoj Federacii. Medicinskij alfavit. 2017; 4 (38): 5–9. (in Russian)Bryers J.D. Medical Biofilms. Biotechnol Bioeng. 2008; 100 (1): 1–18. doi: 10.1002/bit.21838.Bryers J.D. Medical Biofilms. Biotechnol Bioeng. 2008; 100 (1): 1–18. doi: 10.1002/bit.21838.Donlan R.M. Biofilms and device-associated infections. Emerg Infect Dis. 2001; 7 (2): 277–81. doi: 10.3201/eid0702.010226.Donlan R.M. Biofilms and device-associated infections. Emerg Infect Dis. 2001; 7 (2): 277–81. doi: 10.3201/eid0702.010226.Pour N.K., Dusane D.H., Dhakephalkar P.K., Zamin F. R., Zinjarde S.S., Chopade B.A. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol. 2011; 62 (3): 328–338. doi: 10.1111/j.1574-695X.2011.00818.x.Pour N.K., Dusane D.H., Dhakephalkar P.K., Zamin F. R., Zinjarde S.S., Chopade B.A. Biofilm formation by Acinetobacter baumannii strains isolated from urinary tract infection and urinary catheters. FEMS Immunol Med Microbiol. 2011; 62 (3): 328–338. doi: 10.1111/j.1574-695X.2011.00818.x.Haddadin Y.,Annamaraju P.,Regunath H. Central Line Associated Blood Stream Infections. 2022 Nov 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 28613641.Haddadin Y.,Annamaraju P.,Regunath H. Central Line Associated Blood Stream Infections. 2022 Nov 26. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022. PMID: 28613641.Cherry J.D., Yogev R., Harrison G.J., Tan T., Kaplan S.L., Steinbach W.J., Hotez P.J. Infections related to prosthetic or artificial devices. In Feigin, Cherry, Demmier and Kaplan: Textbook of Pediatric Diseases, 7th ed. Elsevier Saunders. 2013; 1015–1043.Cherry J.D., Yogev R., Harrison G.J., Tan T., Kaplan S.L., Steinbach W.J., Hotez P.J. Infections related to prosthetic or artificial devices. In Feigin, Cherry, Demmier and Kaplan: Textbook of Pediatric Diseases, 7th ed. Elsevier Saunders. 2013; 1015–1043.Campoccia D., Montanaro L., Arciola C.R. The significance of infection related to orthopedic devices and issues of antibiotic resistance Biomaterials. 2006; 27 (11): 2331–2339. doi: 10.1016/j.biomaterials.2005.11.044.Campoccia D., Montanaro L., Arciola C.R. The significance of infection related to orthopedic devices and issues of antibiotic resistance Biomaterials. 2006; 27 (11): 2331–2339. doi: 10.1016/j.biomaterials.2005.11.044.Kalita S.J., Verma S. Nanocrystalline hydroxyapatite bioceramic using microwave radiation: synthesis and characterization. Mater Sci Eng C Mater Biol Appl. 2010; 30(2): 295–303. doi: 10.1016/j.msec.2009.11.007.Kalita S.J., Verma S. Nanocrystalline hydroxyapatite bioceramic using microwave radiation: synthesis and characterization. Mater Sci Eng C Mater Biol Appl. 2010; 30(2): 295–303. doi: 10.1016/j.msec.2009.11.007.Harris L.G., Richards R.G. Staphylococci and implant surfaces: a review. Injury. 2006; 37 Suppl 2: 3–14. doi: 10.1016/j.injury.2006.04.003.Harris L.G., Richards R.G. Staphylococci and implant surfaces: a review. Injury. 2006; 37 Suppl 2: 3–14. doi: 10.1016/j.injury.2006.04.003.Teterycz D., Ferry T., Lew D., Stern R., Assal M., Hoffmeyer P., Bernard L., Uckay I. Outcome of orthopedic implant infections due to different staphylococci. Int J Infect Dis. 2010;14 (10): 913–918. doi: 10.1016/j.ijid.2010.05.014.Teterycz D., Ferry T., Lew D., Stern R., Assal M., Hoffmeyer P., Bernard L., Uckay I. Outcome of orthopedic implant infections due to different staphylococci. Int J Infect Dis. 2010;14 (10): 913–918. doi: 10.1016/j.ijid.2010.05.014.Wright J. A., Nair S. P. Interaction of staphylococci with bone. Int J Med Microbiol. 2010; 300 (2–3): 193–204. doi: 10.1016/j.ijmm.2009.10.003.Wright J. A., Nair S. P. Interaction of staphylococci with bone. Int J Med Microbiol. 2010; 300 (2–3): 193–204. doi: 10.1016/j.ijmm.2009.10.003.Rohde H., Burandt E., Siemssen N., Frommelt L., Burdelski C., Wurster S., Stefanie Scherpe S., Davies A.P., Harris L.G., Horstkotte M.A., Knobloch J.K-M., Ragunath Ch., Kaplan J.B., Mack D. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials. 2007; 28 (9): 1711–1720. doi: 10.1016/j.biomaterials.2006.11.046.Rohde H., Burandt E., Siemssen N., Frommelt L., Burdelski C., Wurster S., Stefanie Scherpe S., Davies A.P., Harris L.G., Horstkotte M.A., Knobloch J.K-M., Ragunath Ch., Kaplan J.B., Mack D. Polysaccharide intercellular adhesin or protein factors in biofilm accumulation of Staphylococcus epidermidis and Staphylococcus aureus isolated from prosthetic hip and knee joint infections. Biomaterials. 2007; 28 (9): 1711–1720. doi: 10.1016/j.biomaterials.2006.11.046.Esposito S.,Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int J Antimicrob Agents. 2008; 32 (4): 287–293. doi: 10.1016/j.ijantimicag.2008.03.010Esposito S.,Leone S. Prosthetic joint infections: microbiology, diagnosis, management and prevention. Int J Antimicrob Agents. 2008; 32 (4): 287–293. doi: 10.1016/j.ijantimicag.2008.03.010Umscheid C.A., Mitchell M.D., Doshi J.A., Agarwal R., Williams K., Brennan P.J. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Cont Hosp Epidemiol. 2011; 32 (2): 101–114. doi:10.1086/657912.Umscheid C.A., Mitchell M.D., Doshi J.A., Agarwal R., Williams K., Brennan P.J. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Cont Hosp Epidemiol. 2011; 32 (2): 101–114. doi:10.1086/657912.Cortese Y.J., Wagner V.E., Tierney M., Devine D., Fogarty A. Review of catheter-associatedurinary tract infections and in vitro urinary tract models. J Heal Eng. 2018; 14: 1–16. doi: 10.1155/2018/2986742.Cortese Y.J., Wagner V.E., Tierney M., Devine D., Fogarty A. Review of catheter-associatedurinary tract infections and in vitro urinary tract models. J Heal Eng. 2018; 14: 1–16. doi: 10.1155/2018/2986742.Mandakhalikar К.D., Rahmat J.N., Chiong E.,Neoh K.G., Shen L., Tambyah P.A. Extraction and quantification of biofilm bacteria: method optimized for urinary catheters. Sci Rep 2018; 8 (1): 8069. doi: 10.1038/s41598-018-26342-3.Mandakhalikar К.D., Rahmat J.N., Chiong E.,Neoh K.G., Shen L., Tambyah P.A. Extraction and quantification of biofilm bacteria: method optimized for urinary catheters. Sci Rep 2018; 8 (1): 8069. doi: 10.1038/s41598-018-26342-3.Flores-Mireles A.L., Walker J. N., Caparon M., Hultgren S.J. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Nat Rev Microbiol. 2015; 13 (5): 269–284. doi: 10.1038/nrmicro3432.Flores-Mireles A.L., Walker J. N., Caparon M., Hultgren S.J. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Nat Rev Microbiol. 2015; 13 (5): 269–284. doi: 10.1038/nrmicro3432.Sohail M.R., Uslan D.Z., Khan A.H., Friedman P.A., Hayes D.L., Wilson W.R., Steckelberg J.M., Stoner S.M., Baddour L.M. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007; 45 (2): 166–173. doi: 10.1086/518889.Sohail M.R., Uslan D.Z., Khan A.H., Friedman P.A., Hayes D.L., Wilson W.R., Steckelberg J.M., Stoner S.M., Baddour L.M. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007; 45 (2): 166–173. doi: 10.1086/518889.Baman T.S., Gupta S.K., Valle J.A., Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol. 2009; 2: 129–134. doi: 10.1161/circep.108.816868.Baman T.S., Gupta S.K., Valle J.A., Yamada E. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol. 2009; 2: 129–134. doi: 10.1161/circep.108.816868.Greenspon A.J., Patel J.D., Lau E., Ochoa J.A., Frisch D.R, Ho R.T., Pavri B.B., Kurtz S.M. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011; 58 (10): 1001–1006. doi: 10.1016/j.jacc.2011.04.033.Greenspon A.J., Patel J.D., Lau E., Ochoa J.A., Frisch D.R, Ho R.T., Pavri B.B., Kurtz S.M. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011; 58 (10): 1001–1006. doi: 10.1016/j.jacc.2011.04.033.Cernada M., Brugada M., Golombek S., Vento M. Ventilator-associated pneumonia in neonatal patients: an update. Neonatology. 2014; 105: 98–107. doi: 10.1159/000355539.Cernada M., Brugada M., Golombek S., Vento M. Ventilator-associated pneumonia in neonatal patients: an update. Neonatology. 2014; 105: 98–107. doi: 10.1159/000355539.Pneumatikos I.A., Dragoumanis C.K., Bouros D.E. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology. 2009; 110 (3): 673–680. doi: 10.1097/ALN.0b013e31819868e0.Pneumatikos I.A., Dragoumanis C.K., Bouros D.E. Ventilator-associated pneumonia or endotracheal tube-associated pneumonia? An approach to the pathogenesis and preventive strategies emphasizing the importance of endotracheal tube. Anesthesiology. 2009; 110 (3): 673–680. doi: 10.1097/ALN.0b013e31819868e0.Feldman C., Kassel M., Cantrell J., Kaka S., Morar R., Mahomed A.G., Philips J.I. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation Eur Respir J. 1999; 13 (3): 546–551. doi: 10.1183/09031936.99.13354699.Feldman C., Kassel M., Cantrell J., Kaka S., Morar R., Mahomed A.G., Philips J.I. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation Eur Respir J. 1999; 13 (3): 546–551. doi: 10.1183/09031936.99.13354699.Gil-Perotin S., Ramirez P., Marti V., Sahuquillo J.M., Gonzalez E., Calleja I., Menendez R., Bonastre J. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012; 16 (3): 93. doi: 10.1186/cc11357.Gil-Perotin S., Ramirez P., Marti V., Sahuquillo J.M., Gonzalez E., Calleja I., Menendez R., Bonastre J. Implications of endotracheal tube biofilm in ventilator-associated pneumonia response: a state of concept. Crit Care. 2012; 16 (3): 93. doi: 10.1186/cc11357.Friedland D.R., Rothschild M.A., Delgado M., Isenberg H., Holzman I. Bacterial colonization of endotracheal tubes in intubated neonate. Arch Otolaryngol Head Neck Surg. 2001; 127 (5): 525–528. doi: 10.1001/archotol.127.5.525.Friedland D.R., Rothschild M.A., Delgado M., Isenberg H., Holzman I. Bacterial colonization of endotracheal tubes in intubated neonate. Arch Otolaryngol Head Neck Surg. 2001; 127 (5): 525–528. doi: 10.1001/archotol.127.5.525.Trejo-Hernández A., Andrade-Domínguez A., Hernández M., Encarnación S. Interspecies competition triggers virulence and mutability in Candida albicans — Pseudomonas aeruginosa mixed biofilms. ISME J. 2014; 8 (10): 1974–1988. doi: 10.1038/ismej.2014.53.Trejo-Hernández A., Andrade-Domínguez A., Hernández M., Encarnación S. Interspecies competition triggers virulence and mutability in Candida albicans — Pseudomonas aeruginosa mixed biofilms. ISME J. 2014; 8 (10): 1974–1988. doi: 10.1038/ismej.2014.53.Rodrigues M.E., Lopes S.P., Pereira C.R., Azevedo N.F., Lourenço A., Henriques M., Pereira M.O. Polymicrobial ventilator-associated pneumonia: Fighting in vitro Candida albicans-pseudomonas aeruginosa biofilms with antifungal-antibacterial combination therapy. PLoS One. 2017; 12 (1): e0170433. doi: 10.1371/journal.pone.0170433.Rodrigues M.E., Lopes S.P., Pereira C.R., Azevedo N.F., Lourenço A., Henriques M., Pereira M.O. Polymicrobial ventilator-associated pneumonia: Fighting in vitro Candida albicans-pseudomonas aeruginosa biofilms with antifungal-antibacterial combination therapy. PLoS One. 2017; 12 (1): e0170433. doi: 10.1371/journal.pone.0170433.Hamet M.,Pavon A., Dalle F.,Pechinot A., Prin S.,Quenot J.-P.,Charles P.-E. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia Intensive Care Med. 2012; 38 (8): 1272–1279. doi: 10.1007/s00134-012-2584-2.Hamet M.,Pavon A., Dalle F.,Pechinot A., Prin S.,Quenot J.-P.,Charles P.-E. Candida spp. airway colonization could promote antibiotic-resistant bacteria selection in patients with suspected ventilator-associated pneumonia Intensive Care Med. 2012; 38 (8): 1272–1279. doi: 10.1007/s00134-012-2584-2.Решедько Г.К., Рябкова Е.Л., Кречикова О.И. и др. Резистентность к антибиотикам грамотрицательных возбудителей нозокомиальных инфекций в ОРИТ многопрофильных стационаров России. Клиническая микробиология и антимикробная химиотерапия. 2008; 10 (2): 96–112.Reshedko G.K., Ryabkova E.L., Krechikova O.I. et al. Rezistentnost' k antibiotikam gramotricatel'nyh vozbuditelej nozokomial'nyh infekcij v ORIT mnogoprofil'nyh stacionarov Rossii. Klinicheskaya Mikrobiologiya i Antimikrobnaya Himioterapiya. 2008; 10 (2): 96–112. (in Russian)Morozova V.V., Vlassov V.V.,Tikunova N.V. Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol 2018; 9: 1696. doi: 10.3389/fmicb.2018.01696.Morozova V.V., Vlassov V.V.,Tikunova N.V. Applications of bacteriophages in the treatment of localized infections in humans. Front Microbiol 2018; 9: 1696. doi: 10.3389/fmicb.2018.01696.Haq I.U., Chaudhry W.N., Akhtar M.N., Andleeb S., Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virol J. 2012; 9: 9. doi: 10.1186/1743-422X-9-9.Haq I.U., Chaudhry W.N., Akhtar M.N., Andleeb S., Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virol J. 2012; 9: 9. doi: 10.1186/1743-422X-9-9.Асланов Б.И., Любимова А.В., Зуева Л.П. Бактериофаги как эффективные противоэпидемические средства для купирования вспышек внутрибольничных инфекций. Журнал инфектологии. 2019; 11 (1): 65–70. doi: 10.22625/2072-6732-2019-11-1-65-70Aslanov B.I., Lubimova A.V., Zueva L.P. Bacteriophages as effective antiepidemic agents for control of hospital-acquired infection outbreaks. Journal Infectology. 2019; 11 (1): 65–70. doi: 10.22625/2072-6732-2019-11-1-65-70. (in Russian)Прокопенко Е.И., Щербакова Е.О., Ватазин А.В., Будникова Н.Е., Янковой А.Г., Будникова Н.Е., Агафонова С.Г. Применение бактериофага для лечения гнойно-септических осложнений у больной с почечным аллотрансплантатом. Урология. 2005; 6: 43–46.Prokopenko E.I., Shcherbakova E.O., Vatazin A.V., Budnikova N.E., Yankovoy A.G., Budnikova N.E., Agafonova S.G. Primenenie bakteriofaga dlya lecheniya gnojno-septicheskih oslozhnenij u bol'noj s pochechnym allotransplantatom. Urologiya. 2005; 6: 43–46. (in Russian)Chan B.K., Turner P.E., Kim S., Mojibian H.R., Elefteriades J.A., Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018; 2018 (1): 60–66. doi: 10.1093/emph/eoy005.Chan B.K., Turner P.E., Kim S., Mojibian H.R., Elefteriades J.A., Narayan D. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health. 2018; 2018 (1): 60–66. doi: 10.1093/emph/eoy005.Аникина Т.А., Рязанова С.Х., Сергеева Е.Н. Свежевыделенные штаммы возбудителей — важнейший компонент производства адаптированных лечебно-профилактических бактериофагов. «ИмБио». Нижний Новгород: Вакцинология, 2006; 3Anikina T.A., Ryazanova S.Kh., Sergeeva E.N. Svezhevydelennye shtammy vozbuditelej — vazhnejshij komponent proizvodstva adaptirovannyh lechebno-profilakticheskih bakteriofagov. «ImBio». Nizhnij Novgorod, 2006; 3 (in Russian)Abul-Hassan H.S., El-Tahan K., Massoud B., Gomaa R. Bacteriophage therapy of Pseudomonas burn wound sepsis. Ann. Mediterr Burn Club. 1990; 3: 262–264.Abul-Hassan H.S., El-Tahan K., Massoud B., Gomaa R. Bacteriophage therapy of Pseudomonas burn wound sepsis. Ann. Mediterr Burn Club. 1990; 3: 262–264.Slopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz). 1987; 35: 569–583.Slopek S., Weber-Dabrowska B., Dabrowski M., Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981–1986. Arch Immunol Ther Exp (Warsz). 1987; 35: 569–583.Гостищев В.К., Станоевич У.С., Алешкин В.А., Афанасьев С.С., Воропаева Е.А.,Шкроб Л.О.,Матвиевская Н.С.,Попов Д.В. Третичный перитонит: возможности его профилактики. Хирургия. 2007; 9: 15–18.Gostishchev V.K., Stanoevich U.S., Aleshkin V.A., Afanasiev S.S., Voropaeva E.A., Shkrob L.O., Matvievskaya N.S., Popov D.V. Tretichnyj peritonit: vozmozhnosti ego profilaktiki. Hirurgiya. 2007; 9: 15–18. (in Russian)Хайруллин И.Н., Поздеев О.К., Шаймарданов Р.Ш. Эффективность применения специфических бактериофагов в лечении и профилактике хирургических послеоперационных инфекций. Казанский мед. журнал. 2002; 4: 258–261.Khairullin I.N., Pozdeev O.K., Shaimardanov R.Sh. Effektivnost' primeneniya specificheskih bakteriofagov v lechenii i profilaktike hirurgicheskih posleoperacionnyh infekcij. Kazanskij Med Zhurnal. 2002; 4: 258–261. (in Russian)Cao F., Wang X., Wang L., Li Z., Che J., Wang L., Li X., Cao Z., Zhang J., Jin L.,Xu Y. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int. 2015; 2015: 752930. doi: 10.1155/2015/752930.Cao F., Wang X., Wang L., Li Z., Che J., Wang L., Li X., Cao Z., Zhang J., Jin L.,Xu Y. Evaluation of the efficacy of a bacteriophage in the treatment of pneumonia induced by multidrug resistance Klebsiella pneumoniae in mice. Biomed Res Int. 2015; 2015: 752930. doi: 10.1155/2015/752930.Hung C.H., Kuo C.F., Wang C.H., Wu C.M., Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother. 2011; 55: 1358–1365. doi: 10.1128/AAC.01123-10.Hung C.H., Kuo C.F., Wang C.H., Wu C.M., Tsao N. Experimental phage therapy in treating Klebsiella pneumoniae-mediated liver abscesses and bacteremia in mice. Antimicrob Agents Chemother. 2011; 55: 1358–1365. doi: 10.1128/AAC.01123-10.Chadha P.,Katare O.P., Chhibber S. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog. 2016; 99: 68–77. doi: 10.1016/j.micpath.2016.08.001.Chadha P.,Katare O.P., Chhibber S. In vivo efficacy of single phage versus phage cocktail in resolving burn wound infection in BALB/c mice. Microb Pathog. 2016; 99: 68–77. doi: 10.1016/j.micpath.2016.08.001.Hesse S., Rajaure M., Wall E., Johnson J., Bliskovsky V., Gottesman S., Adhya S. Phage resistance in multidrug-resistant Klebsiella pneumoniae ST258 evolves via diverse mutations that culminate in impaired adsorption. mBio. 2020; 11 (1): e02530–19. doi: 10.1128/mBio.02530-19.Hesse S., Rajaure M., Wall E., Johnson J., Bliskovsky V., Gottesman S., Adhya S. Phage resistance in multidrug-resistant Klebsiella pneumoniae ST258 evolves via diverse mutations that culminate in impaired adsorption. mBio. 2020; 11 (1): e02530–19. doi: 10.1128/mBio.02530-19.Zimecki M., Artym J., Kocieba M., Weber-Dabrowska B., Borysowski J., Górski A. Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. Med Microbiol Immunol. 2010; 199 (2): 71–79. doi: 10.1007/s00430-009-0135-4.Zimecki M., Artym J., Kocieba M., Weber-Dabrowska B., Borysowski J., Górski A. Prophylactic effect of bacteriophages on mice subjected to chemotherapy-induced immunosuppression and bone marrow transplant upon infection with Staphylococcus aureus. Med Microbiol Immunol. 2010; 199 (2): 71–79. doi: 10.1007/s00430-009-0135-4.Vinodkumar C.S., Kalsurmath S., Neelagund Y.F. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol. 2008; 51 (3): 360–366. doi: 10.4103/0377-4929.42511.Vinodkumar C.S., Kalsurmath S., Neelagund Y.F. Utility of lytic bacteriophage in the treatment of multidrug-resistant Pseudomonas aeruginosa septicemia in mice. Indian J Pathol Microbiol. 2008; 51 (3): 360–366. doi: 10.4103/0377-4929.42511.Morello E., Saussereau E., Maura D., Huerre M., Touqui L., Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fi brosis strains: fi rst steps towards treatment and prevention. PLoS One. 2011 Feb 15; 6 (2): e16963. doi: 10.1371/journal.pone.0016963.Morello E., Saussereau E., Maura D., Huerre M., Touqui L., Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fi brosis strains: fi rst steps towards treatment and prevention. PLoS One. 2011 Feb 15; 6 (2): e16963. doi: 10.1371/journal.pone.0016963.Габриэлян Н.И.,Горская Е.М.,Цирульникова О.М. Возможности использования бактериофагов в хирургии и трансплантологии. Вестник трансплантологии и искусственных органов. 2012; 1 (14): 106–113.Gabrielyan N.I., Gorskaya E.M., Tsirulnikova O.M. Vozmozhnosti ispol'zovaniya bakteriofagov v hirurgii i transplantologii. Vestnik Transplantologii i Iskusstvennyh Organov. 2012; 1 (14): 106–113 (in Russian)Nelson D., Loomis L., Fischetti V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A. 2001; 98 (7): 4107–4112. doi: 10.1073/pnas.061038398.Nelson D., Loomis L., Fischetti V.A. Prevention and elimination of upper respiratory colonization of mice by group A streptococci by using a bacteriophage lytic enzyme. Proc Natl Acad Sci U S A. 2001; 98 (7): 4107–4112. doi: 10.1073/pnas.061038398.Raz A., Serrano A., Lawson C., Thaker M., Alston T.,Bournazos S., Ravetch J.V., Fischetti V.A. Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. PNAS. 2017; 114 (18): 4781–4786. doi: 10.1073/pnas.1619249114.Raz A., Serrano A., Lawson C., Thaker M., Alston T.,Bournazos S., Ravetch J.V., Fischetti V.A. Lysibodies are IgG Fc fusions with lysin binding domains targeting Staphylococcus aureus wall carbohydrates for effective phagocytosis. PNAS. 2017; 114 (18): 4781–4786. doi: 10.1073/pnas.1619249114.Raz A., Serrano A., Thaker M., Alston T.,Fischetti V.A. Lysostaphin lysibody leads to effective opsonization and killing of methicillin-resistant Staphylococcus aureus in a murine model. Antimicrob Agents Chemother. 2018; 62 (10): e01056–18. doi: 10.1128/AAC.01056-18.Raz A., Serrano A., Thaker M., Alston T.,Fischetti V.A. Lysostaphin lysibody leads to effective opsonization and killing of methicillin-resistant Staphylococcus aureus in a murine model. Antimicrob Agents Chemother. 2018; 62 (10): e01056–18. doi: 10.1128/AAC.01056-18.Алешкин А.В., Селькова Е.П., Ершова О.Н., Савин И.А., Шкода А.С., Бочкарева С.С., Митрохин С.Д., Киселева И.А., Орлова О.Е.,Рубальский Е.О.,Зулькарнеев Э.Р. Концепция персонализированной фаготерапии пациентов отделения реанимации и интенсивной терапии, страдающих инфекциями, связанными с оказанием медицинской помощи. Фундаментальная и клиническая медицина. 2018; 2 (3): 66–74.Aleshkin A.V., Selkova E.P., Ershova O.N., Savin I.A., Skoda A.S., Bochkareva S.S., Mitrokhin S.D., Kiseleva I.A., Orlova O .E., Rubalsky E.O., Zulkarneev E.R. Koncepciya personalizirovannoj fagoterapii pacientov otdeleniya reanimacii i intensivnoj terapii, stradayushchih infekciyami, svyazannymi s okazaniem medicinskoj pomoshchi. Fundamental'naya i Klinicheskaya Medicina. 2018; 2 (3); 66–74. (in Russian)Тапальский Д.В. Препараты бактериофагов и комбинации антибиотиков: in vitro активность в отношении изолятов Pseudomonas aeruginosa ST235 с экстремальной антибиотикорезистентностью. Клиническая микробиология и антимикробная химиотерапия. 2016; 4 (18): 242–248.Tapalsky D.V. Preparaty bakteriofagov i kombinacii antibiotikov: in vitro aktivnost' v otnoshenii izolyatov Pseudomonas aeruginosa ST235 s ekstremal'noj antibiotikorezistentnost'yu. Klinicheskaya Mikrobiologiya i Antimikrobnaya Himioterapiya. 2016; 4 (18): 242–248. (in Russian)Yerushalmy O., Khalifa L., Gold N., Rakov C., Alkalay-Oren S., Adler K., Ben-Porat Sh., Kraitman R., Gronovich N., Ginat K. Sh., Abdalrhman M., Coppenhagen-Glazer Sh., Nir-Paz R., Hazan R. The israeli phage bank (IPB). Antibiotics (Basel). 2020; 9 (5): 269. doi: 10.3390/antibiotics9050269.Yerushalmy O., Khalifa L., Gold N., Rakov C., Alkalay-Oren S., Adler K., Ben-Porat Sh., Kraitman R., Gronovich N., Ginat K. Sh., Abdalrhman M., Coppenhagen-Glazer Sh., Nir-Paz R., Hazan R. The israeli phage bank (IPB). Antibiotics (Basel). 2020; 9 (5): 269. doi: 10.3390/antibiotics9050269.Letarov A.V., Kulikov E.E. Determination of the bacteriophage host range: culture-based approach. Methods Mol Biol. 2018; 1693: 75–84. doi: 10.1007/978-1-4939-7395-8_7.Letarov A.V., Kulikov E.E. Determination of the bacteriophage host range: culture-based approach. Methods Mol Biol. 2018; 1693: 75–84. doi: 10.1007/978-1-4939-7395-8_7.Merabishvili M., Pirnay J.P., De Vos D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 2018; 1693: 99–110. doi: 10.1007/978-1-4939-7395-8_9.Merabishvili M., Pirnay J.P., De Vos D. Guidelines to compose an ideal bacteriophage cocktail. Methods Mol. Biol. 2018; 1693: 99–110. doi: 10.1007/978-1-4939-7395-8_9.Hesse S., Adhya S. Phage therapy in the twenty-first century: facing the decline of the antibiotic Era; is it finally time for the age of the phage? Annu Rev Microbiol. 2019; 73: 155–174. doi: 10.1146/annurev-micro-090817-062535.Hesse S., Adhya S. Phage therapy in the twenty-first century: facing the decline of the antibiotic Era; is it finally time for the age of the phage? Annu Rev Microbiol. 2019; 73: 155–174. doi: 10.1146/annurev-micro-090817-062535.Kortright K.E., Chan B.K., Koff J.L., Turner P.E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019; 25: 219–232. doi: 10.1016/j.chom.2019.01.014.Kortright K.E., Chan B.K., Koff J.L., Turner P.E. Phage therapy: a renewed approach to combat antibiotic-resistant bacteria. Cell Host Microbe. 2019; 25: 219–232. doi: 10.1016/j.chom.2019.01.014.Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 2008; 197: 1079–1081. doi: 10.1086/533452.Rice L.B. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 2008; 197: 1079–1081. doi: 10.1086/533452.Mann N.H. The potential of phages to prevent MRSA infections. Res Microbiol. 2008; 159: 400–405. doi: 10.1016/j.resmic.2008.04.003.Mann N.H. The potential of phages to prevent MRSA infections. Res Microbiol. 2008; 159: 400–405. doi: 10.1016/j.resmic.2008.04.003.Leszczyński P., Weber-Dabrowska B., Kohutnicka M., Luczak M., Górski A. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker — case report. Folia Microbiol (Praha). 2006; 51: 236–238. doi: 10.1007/BF02932128.Leszczyński P., Weber-Dabrowska B., Kohutnicka M., Luczak M., Górski A. Successful eradication of methicillin-resistant Staphylococcus aureus (MRSA) intestinal carrier status in a healthcare worker — case report. Folia Microbiol (Praha). 2006; 51: 236–238. doi: 10.1007/BF02932128.

The authors declare that there are no conflicts of interest present.